Valuation: Iqvia Holdings

Market Cap 44.09B 39.29B 36.37B 32.92B 62.02B 4,160B 62.75B 436B 171B 2,187B 165B 162B 6,969B P/E 2026 *
35.2x
P/E 2027 * 28.2x
Enterprise Value 57.98B 51.67B 47.83B 43.29B 81.56B 5,471B 82.52B 574B 225B 2,876B 218B 213B 9,164B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 3.11x
Free-Float
62.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 02/10/2016
Director of Finance/CFO 51 27/02/2026
Chief Tech/Sci/R&D Officer - 31/12/2025
Director TitleAgeSince
Director/Board Member 68 04/02/2015
Chairman 64 02/10/2016
Director/Board Member 69 02/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+2.60% - - 44.09B
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.46%+4.78%+51.93%+123.00% 43.06B
Weighted average by Cap. +0.50%+4.67%+51.28%+127.77%

Financials

2026 *2027 *
Net sales 17.42B 15.52B 14.37B 13B 24.5B 1,643B 24.79B 172B 67.59B 864B 65.33B 63.97B 2,753B 18.47B 16.46B 15.24B 13.79B 25.98B 1,743B 26.29B 183B 71.68B 916B 69.28B 67.84B 2,919B
Net income 1.3B 1.16B 1.07B 969M 1.83B 122B 1.85B 12.83B 5.04B 64.36B 4.87B 4.77B 205B 1.6B 1.43B 1.32B 1.2B 2.26B 151B 2.28B 15.87B 6.23B 79.58B 6.02B 5.89B 254B
Net Debt 13.89B 12.38B 11.46B 10.37B 19.54B 1,311B 19.77B 137B 53.92B 689B 52.11B 51.03B 2,196B 13.33B 11.88B 11B 9.95B 18.75B 1,258B 18.97B 132B 51.74B 661B 50.01B 48.97B 2,107B
Logo Iqvia Holdings
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Iqvia Holdings